The new neuromodulator daxibotulinumtoxinA-lanm (Daxxify) may be comparable and potentially longer-lasting than the standard cosmetic botulinum toxin (Botox), according to an article published in Women’s Health. Experts explained that Daxxify has already proven to be 200% more effective than other cosmetic options, promising to last up to 6 to 9 months. The medication—injected into five points across the patient’s forehead—works by smoothing glabellar lines with the protein botulinum toxin type A. However, instead of using the standard human serum albumin to aid the protein in bonding with nerve endings, Daxxify utilizes a positively charged synthetic peptide to encourage stronger bonding and prolong the effects of the medication. The experts suggested that individuals who have unwanted facial wrinkles and are limited on time for cosmetic appointments should consider consulting their dermatologist about Daxxify; however, they advised individuals who are pregnant to avoid receiving the injections. Patients who receive Daxxify may experience side effects such as bruising, swelling, headaches, and eyelid and eyebrow ptosis. Daxxify was approved by the FDA in September 2022 and is expected to become widely available in late 2023.
April 30, 2023